Partnerships

Our goal at Fluicell is to transform medicine, using our universal tissue production platform to create innovative solutions for regenerative medicine and drug discovery. Our Nexocyte platform makes it possible to construct tissue therapeutics and human screening products to defeat serious disease.

To realize the full potential of our platform, we seek to partner with innovation-driven pharmaceutical companies to bring our current therapeutic products to patients and to extend our development to new therapeutic areas.
‍
We strive to create long-term collaborations based on joint innovation and mutual benefit. Contact us to learn more about our partnering opportunities.

What we offer

Tissue production platform

Our platform is based on our unique bioprinting technology with single-cell precision.

Highly skilled research team

Our research team has extensive disease area expertise and tissue engineering know-how.

Innovative product pipeline

Pipeline with advanced therapeutic and screening product concepts, targeting multiple disease areas.

What we seek

We want to partner with pharmaceutical companies looking to advance the development of regenerative medicine solutions targeting diseases with a large unmet medical need. Our goal is to establish collaborations that can bring our existing product pipeline to patients and to extend our platform to new areas by initiating co-development of tissue-based therapeutics and screening products.

Bioprinted cardiac models

Fluicell has partnered with a major pharmaceutical company to create bioprinted cardiac models that can be used for safety pharmacology screening. The tissues are created using Fluicell’s Nexocyte platform are designed to accurately recreate human cardiac function to better predict potential toxic effects from tested drug compounds. An important development goal in the collaboration is to make it easy to integrate the bioprinted tissues in already existing development workflows.

Download the PDF

Advanced kidney disease model

In the EU-funded partnership Bioprinting on-chip microphysiological models of humanized kidney tubulointerstitium (BIRDIE) Fluicell’s bioprinting technology is combined with organ-on-chip devices and IPSC-based models to develop advanced kidney models with a high degree on cell and organ-level functional mimicry. The primary goal of the project is to create a platform for studying viral infection and for nephrotoxicity applications. BIRDIE is a collaboration between Fluicell, Maastricht University, Nantes University and TissUse GmbH.

Download the PDF

Integrated cardiac toxicity platform

The project An Integrated Platform for Cardiac Toxicology and Efficacy (INTEC) is a collaboration between Fluicell and the Dutch company Cytocytpher BV, aimed at developing a research platform that creates new ways to study cardiac toxicity. The platform brings together advanced cardiac cell analysis tools and localized drug delivery together with automated image analysis and AI algorithms to create new ways to study cardiac function. INTEC combines Fluicell’s microfluidic technology with high throughput cardiac contractile systems for single-cell analysis with the goal to increase drug development efficiency and enable better understanding of cardiac biology.

Download the PDF

Our Partnership Projects

TRUSTED BY INDUSTRY LEADERS

what our customers say

Fluicell’s technology is the first of its kind to enable single-cell resolution bioprinting with precision, speed and reproducible accuracy, even in 3D, in a way that was not possible before.

Dr. Luiz Bertassoni, Director Knight Cancer Precision Biofabrication Hub

The BioPen System is one of the best single-cell treatment systems on the market. It is easy-to-use, and gives me beautiful, publication-ready movies.

Dr. Dani Cai, National Institute of Health

The BioPen system provides us with unique data; with it, you are able to see how cell processes are trapped.

Prof. Megan Rizzo, University of Maryland Medical Center

The BioPen product is well designed and works even better than we could have hoped. The team is very reliable with customer support. I would highly recommend purchasing this product.

Dr. Veronica Jove, Rockefeller University

The Dynaflow Resolve system is a very reliable and efficient tool for automated compound application with excellent performance in fast solution exchange.

Dr. Timm Danker, NMI TT

Platform

Learn more about Fluicell’s universal tissue production platform, based on our high-resolution single-cell bioprinting technology Biopixlar.

Pipeline

Our pipeline consists of products based on our tissue production platform, including tissue-based therapeutics for type 1 diabetes treatment, and cardiac toxicity and kidney disease screening models.

Partner with us!

Learn about what we hope to achieve in partnership with innovation-driven pharmaceutical companies. Have questions or interested in exploring a collaboration? Get in touch.